Malignant pleural disease.
| Autor: | Piggott LM; Department of Respiratory Medicine, Tallaght University Hospital, Dublin, Ireland.; Department of Respiratory Medicine, St. James's Hospital, Dublin, Ireland.; These authors contributed equally., Hayes C; Department of Respiratory Medicine, Tallaght University Hospital, Dublin, Ireland.; Department of Respiratory Medicine, St. James's Hospital, Dublin, Ireland.; These authors contributed equally., Greene J; Department of Oncology, Tallaght University Hospital, Dublin, Ireland., Fitzgerald DB; Department of Respiratory Medicine, Tallaght University Hospital, Dublin, Ireland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Breathe (Sheffield, England) [Breathe (Sheff)] 2023 Dec; Vol. 19 (4), pp. 230145. Date of Electronic Publication: 2024 Feb 13. |
| DOI: | 10.1183/20734735.0145-2023 |
| Abstrakt: | Malignant pleural disease represents a growing healthcare burden. Malignant pleural effusion affects approximately 1 million people globally per year, causes disabling breathlessness and indicates a shortened life expectancy. Timely diagnosis is imperative to relieve symptoms and optimise quality of life, and should give consideration to individual patient factors. This review aims to provide an overview of epidemiology, pathogenesis and suggested diagnostic pathways in malignant pleural disease, to outline management options for malignant pleural effusion and malignant pleural mesothelioma, highlighting the need for a holistic approach, and to discuss potential challenges including non-expandable lung and septated effusions. Competing Interests: Conflict of interest: All authors have reported that no potential conflicts of interest exist with any companies/organisations whose products or services may be discussed in this article. (Copyright ©ERS 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|